linjc16/ctgov huggingface dataset:
Degrees of New ICT Use Among Surgical Patients

Study Overview
=================
Brief Summary
-----------------
In recent years, the trend is for the patient to participate in their care. The development of new technologies together with the opportunities to exchange information, control one's own health and the possibility of communication between the team and the patient have increased. This is a prospective study trying to know the real use of ICT (information and communication technologies) among our surgical patients, its ability to use it and the differences in terms of gender, age or social range between others

Official Title
-----------------
Degrees of New Information and Communication Technologies (ICT) Use Among Surgical Patients (NINASPA Study)

Conditions
-----------------
Surgical Procedure, Unspecified

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years scheduled to surgery in our Department Exclusion Criteria: Inability to read Inability to understand messages Emergency surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Survey|A dedicated survey on the use of mobile applications to all patients who were to be operated on a scheduled basis in our Surgery Service|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Use of ITC | Number of patients with access to Internet | 6-12 months | 
| Rate of Use Health applications | Number of patients with an Health app | 6-12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of acceptance of ITC | Degree of ITC use on a diary basis | 6-12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Surgery, Elderly patient, New technologies
Activity Monitoring Assessment of Opiate Withdrawal - 4

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if hyperactivity accompanies abrupt opiate withdrawal in heroin addicts, to determine if computerized solid state activity monitors are capable of quantifying hyperactivity, and to quantify the physical and affective symptoms occurring during abrupt withdrawal in heroin addicts and morphine's capacity to alleviate these symptoms.

Official Title
-----------------
Activity Monitoring Assessment of Opiate Withdrawal

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Morphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Depression |  |  | 
| Anxiety |  |  | 
| Withdrawal severity |  |  | 
| Activity |  |  | 
| Opiate secondary withdrawal |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
opioid dependence
PostmenopausAL heaLth And DIseAse (PALLADIA) Study

Study Overview
=================
Brief Summary
-----------------
This is a prospective study of the incidence and risk factors of chronic diseases that are associated with menopause.

Official Title
-----------------
PostmenopausAL heaLth And DIseAse (PALLADIA) Study: Prospective Study of the Incidence and Risk Factors of Chronic Diseases Associated With Menopause

Conditions
-----------------
Menopause

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women Exclusion Criteria: Men Women of reproductive age

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular death |  | up to 2025 | 
| Coronary heart disease |  | up to 2025 | 
| Stroke |  | up to 2025 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diabetes mellitus |  | up to 2025 | 
| Osteoporotic fractures |  | up to 2025 | 
| Breast cancer |  | up to 2025 | 
| Any cancer |  | up to 2025 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
menopause
Diaphragm Ultrasound in Neuromuscular Disorders

Study Overview
=================
Brief Summary
-----------------
Muscular dystrophies are neurologic disease with higher morbidity and mortality. Cardiac function and respiratory muscles can be affected, in addition with skeletal muscle deficiency . Lung function is classically assessed with functionnal pulmonary tests (FPT) . Ultrasound recently emerged as a non-invasive tool to assess diaphragm function. The aims of the study are: to provide the spectrum of diaphragm ultrasound in patients with muscular dystrophies to assess the correlation between diaphragm ultrasound and FPT to assess the correlation between diaphragm ultrasound and cardiac function

Official Title
-----------------
Diaphragm Ultrasound in Neuromuscular Disorders

Conditions
-----------------
Muscular Dystrophies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Duchenne muscular dystrophy, Becker muscular dystrophy, LGMD, myotonic dystrophy type 1 and type 2, metabolic myopathy, mitochondrial myopathy, FSHD1 and 2, myasthenia Exclusion Criteria: history of cardiac surgery history of thoracic surgery brain traumatism
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diaphragm ultrasound motion | using echography | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between diaphragm motion (mm) and forced vital capacity(ml) | using echography and FPT | 1 year | 
| correlation between diaphragm motion (mm) and inspiratory capacity (ml) | using echography and FPT | 1 year | 
| diaphragm thickness (mm) | using echography | 1 year | 
| correlation between diaphargm thickness and maximal inspiratory pressure (cmH20) | using echography and FPT | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diaphragm, ultrasound, echocardiography
The Use of L-Carnitine And CoQ10 Supplements In the Treatment of Cyclic Vomiting Syndrome (CVS)

Study Overview
=================
Brief Summary
-----------------
This is a study with the principle goal being to learn about the use of L-Carnitine and CoQ10, two vitamin supplements that are currently being used to treat Cyclic Vomiting Syndrome, largely initiated by parents. We want to learn how effective these supplements are compared to standard treatment, at what dose, and what onset of action in order to initiate future prospective study on these supplements.

Official Title
-----------------
Co-Enzyme Q10, L-Carnitine and Amitriptyline Usage in Cyclic Vomiting Syndrome (CVS): A Research Study

Conditions
-----------------
Cyclic Vomiting Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3 discrete episodes of vomiting normal health between episodes stereotypical clinical pattern no abnormal test results to account for vomiting (see exclusion criteria) Exclusion Criteria: abnormal UGI with small bowel follow-through revealing an anatomic anomaly, inflammatory or obstructive Significantly abnormal endoscopic biopsies (moderate to severe esophagitis, H. pylori) Abnormal abdominal ultrasound revealing hydronephrosis, cholelithiasis, pancreatitis Positive screening for endocrine disorder (diabetic ketoacidosis, Addison's) Positive screening for inborn errors of metabolism (hypoglycemia, lactic acidosis, hyperammonemia, organic acidemia, amino aciduria, elevated beta-ALA, porphobilinogen)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>The General Questionnaire: help to understand which characteristics of CVS patients are associated with both beneficial and harmful effects of these treatments | |
| 2<br>The Co-Enzyme Q10 Questionnaire: to be completed by individuals who ever taken co-enzyme Q10 | |
| 3<br>The L-Carnitine Questionnaire: to be completed by individuals who have ever taken L-carnitine | |
| 4<br>The Amitriptyline Questionnaire: to be completed by individuals who have ever taken amitriptyline | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| How two vitamin supplements are being used to treat cyclic vomiting syndrome |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| How effective these supplements appear to be compared to standard treatment |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Learn, L-Carnitine, Co-enzyme Q10, Effective, These supplements, Compared, Standard
Genetic Characterisation of High-grade Paediatric Osteosarcomas

Study Overview
=================
Brief Summary
-----------------
At present, the only recognised prognostic factor for primary high-grade osteosarcoma is the histological response to preoperative chemotherapy. Our study was designed to identify new diagnostic markers that could eventually have a prognostic value and therapeutic consequences. 80 patients under 20 years of age with primary osteosarcomas were studied while under treatment by the French Society of Paediatric Oncology OS 94 protocol. Paired normal and biopsy samples were collected. In addition, surgical resection specimens, following preoperative chemotherapy, were obtained in many cases. After genomic DNA extraction, an allelotyping analysis targeting microsatellites was planned. The studied DNA regions contained mainly Rb, p53, APC, p16, c-met, TWIST, c-kit, erbB2 and topoisomerases genes. The techniques used in this molecular analysis comprised mainly allelotyping study, quantitative real-time PCR, gene sequencing , immunohistochemistry. The first results showed the prognostic value of 7q31 region containing c-met and 5q21 containing APC (Br J Cancer, 2003, Entz-Werlé et al.), 7p21 containing TWIST (Int J Cancer, 2005, Entz-Werlé et al.) and 4q21 targeting c-kit gene (J Clin Oncol, 2005, Entz-Werlé et al.).

Official Title
-----------------
Study of Prognostic Value by Molecular Analysis in Paediatric Osteosarcomas of the Chromosomal Regions Containing Rb, p16, p53, Cycline D1, APC, erbB2 and C-met Genes

Conditions
-----------------
Paediatric Osteosarcomas

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients under 20 years of age with primary osteosarcomas Under treatment by the French Society of Paediatric Oncology OS 94 protocol

Ages Eligible for Study
-----------------
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of molecular abnormalities statistically linked to survival or response to chemotherapy |  |  |
Verbal Encouragement in Swimming

Study Overview
=================
Brief Summary
-----------------
Verbal encouragement (VE) is used to enhance the performance in several sports, even though no studies have been conducted in swimmers and no effects have been reported in elite athletes by some Authors. Besides influencing motor performance, VE is also known to enhance the physical load, thus increasing the probability of developing fatigue. The aim of this research was to study VE in swimmers by evaluating both chronometric performance and muscle fatigue (using sEMG).

Official Title
-----------------
The Effect of Verbal Encouragement on Performance and Muscle Fatigue in Swimming

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: with verbal encouragement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 1 year of experience in training aimed at regional and international competitions a score ≥ 200 points on the personal best in the 200m freestyle, in accordance with the international point score (IPS) (http://www. swimnews.com/ipspoints) being healthy Exclusion Criteria: having a disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: with verbal encouragement<br> | Other: with verbal encouragement<br>* Each athlete swam a maximal 200m freestyle trial in two different conditions: one trial with verbal encouragement and the other without verbal encouragement<br>|
| No Intervention: without verbal encouragement<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| swimming velocity | m/sec | up to 2min 30s | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pectoralis Major muscle fatigue | time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal measured for Pectoralis Major muscle | up to 2min 30s | 
| Triceps Brachii muscle fatigue | time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal measured for Triceps Brachii muscle | up to 2min 30s | 
| Latissimus Dorsi muscle fatigue | time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal measured for Latissimus Dorsi muscle | up to 2min 30s | 
| Rectus Femoris muscle fatigue | time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal measured for Rectus Femoris muscle | up to 2min 30s | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
verbal encouragement, performance, muscle fatigue, swimming, sEMG
The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

Study Overview
=================
Brief Summary
-----------------
One important clinical challenge in older individuals is maintaining mobility in the absence of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility. Conventional therapies have only modest effect in improving symptoms. The investigators hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.

Official Title
-----------------
The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

Conditions
-----------------
Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Drug: Ramipril


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ankle-brachial index of <0.9 at rest in at least one leg History of intermittent claudication (unilateral or bilateral) which was stable for 6 months Evidence of superficial femoral artery stenosis or occlusion on duplex scan Blood pressure <=160/90 mmHg Stable medication regimen for at least 6 months and not previously treated with ACE inhibitors Exclusion Criteria: Limiting coronary artery disease Renal Failure History of hypertension History of type 2 diabetes mellitus

Ages Eligible for Study
-----------------
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ramipril|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to onset of claudication |  |  | 
| Total exercise time during a standard treadmill test |  |  | 
| Walking ability measured using the standard Walking Impairment Questionnaire |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leg Blood Flow using Duplex Ultrasound |  |  |
Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to find out if taking a dose of gabapentin 600 mg by mouth (po) before surgery will help prevent the development of tourniquet pain and hypertension while the tourniquet is inflated during orif of tibia fracture.

Official Title
-----------------
Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension During Orif of Tibia Fracture Under General Anesthesia

Conditions
-----------------
Tourniquet-induced Hypertension, Tourniquet-induced Pain

Intervention / Treatment
-----------------
* Drug: gabapentin 600 mg po
* Drug: Placebo pill given one hour before surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient ages 18-64 ASA physical status 1-3 Schedule for orif tibia fracture with use of pneumatic tourniquet Exclusion Criteria: Allergy to study medications polytrauma lower extremity crush injury chronic opioid use sickle cell disease or trait peripheral vascular disease poorly controlled hypertension history of DVT/PE morbid obesity (BMI > 35) patient or surgeon refusal patient inability to properly describe postoperative pain to investigators

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gabapentin<br>Gabapentin 600 mg po given 1 hour before surgery | Drug: gabapentin 600 mg po<br>* Given one hour before surgery<br>|
| Placebo Comparator: Placebo sugar pill<br> | Drug: Placebo pill given one hour before surgery<br>* Placebo pill given<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of tourniquet-induced hypertension | Primary outcome is incidence of tourniquet-induced hypertension, which is defined as an increase of systolic or diastolic blood pressure > 30% from baseline. This will be looked at during the time of tourniquet inflation (from inflation to deflation) during the actual surgical procedure. Usual maximum inflation time is 120 minutes. | During the tourniquet inflation time period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain | Postoperative pain scores for 24 hours after surgery | 24 hours | 
| Narcotic use | Total use of morphine, vicodin during 24 hours after surgery | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
narcotic use, Other Acute Pain
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

Study Overview
=================
Brief Summary
-----------------
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.

Conditions
-----------------
Moderate to Severe Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: Q301 Cream
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female subjects aged 18 or older Subjects with a clinical diagnosis of AD according to the Hanifin and Rajka Criteria by a board certified/eligible dermatologist Subjects with IGA score 3 or 4 corresponding to moderate to severe AD at screening and baseline visits Exclusion Criteria: Subjects who had topical treatment with corticosteroids within 1 week before randomization Subjects who had systemic treatment with corticosteroids or cyclosporine or other immunosuppressive treatment within 4 weeks before randomization Subjects who had ultraviolet irradiation (including photopheresis) within 4 weeks before screening Subjects who participated in another drug trial within 4 weeks before screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Q301 Cream<br>Q301 Cream | Drug: Q301 Cream<br> <br> |
| Placebo Comparator: Vehicle<br>Vehicle | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who have the IGA score of 0 or 1 |  | Week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change from baseline on the VAS for pruritus |  | Week 8 | 
| Percent change from baseline on the EASI |  | Week 8 | 
| Percent change from baseline on the SCORAD |  | Week 8 | 
| Percent change from baseline on the DLQI |  | Week 8 |